Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
By Deidre McPhillips, CNN (CNN) — Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs, adults living with obesity or overweight who were taking Zepbound, the brand name for tirzepatide, lost more than
Continue Reading